Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates

Viatris Inc. (VTRS) reported Q2 2025 adjusted EPS of $0.62 and revenues of $3.58 billion, both surpassing consensus estimates, which drove a positive share price reaction despite a 6% year-over-year revenue decrease. Branded drug sales operationally rose 3%, buoyed by strong performance in Greater China and Emerging Markets, while generics sales declined 10% due in part to an FDA import alert impacting its Indore facility. Viatris reiterated its 2025 revenue guidance of $13.5-$14 billion and raised its adjusted EPS forecast to $2.16-$2.30, although the stock remains down nearly 30% year-to-date.

Analysis

Viatris (VTRS) reported mixed second-quarter 2025 results, characterized by a top and bottom-line beat against a backdrop of declining year-over-year performance and significant operational headwinds. The company posted adjusted EPS of $0.62 on revenues of $3.58 billion, surpassing consensus estimates and prompting a positive short-term stock reaction. However, this was tempered by a 6% year-over-year revenue decline (2% on a divestiture-adjusted operational basis) and a drop in adjusted EPS from $0.69 in the prior-year quarter. The stock's significant 29.7% year-to-date decline, which starkly underperforms the industry's 8.6% drop, provides critical context for the results. A clear divergence is evident between the company's segments; Branded Drug sales grew 3% operationally, fueled by a 9% expansion in Greater China, while the Generics business contracted by 10%. This weakness in generics is directly attributed to the negative impact from an FDA warning letter and import alert at its Indore facility. Profitability is also under pressure, with adjusted gross margin falling to 56.3% from 58.4%. Despite these challenges, Viatris provided a key positive signal by raising its full-year 2025 adjusted EPS guidance to a range of $2.16-$2.30 while reaffirming revenue projections and its commitment to shareholder returns through a targeted $500-$650 million in share repurchases.

Key Decisions for Investors

• Investors should weigh the positive catalyst from the Q2 earnings beat and raised full-year EPS guidance against the fundamental challenges of a 6% year-over-year revenue decline and contracting gross margins.
• Closely monitor the performance of the generics segment and any developments regarding the FDA import alert on the Indore facility, as this remains a significant operational headwind and a key driver of the 10% decline in generics revenue.
• Evaluate the company's ability to capitalize on growth in its Branded Drugs segment, particularly in Greater China, and the effectiveness of its share repurchase program as potential offsets to the stock's ongoing underperformance and operational issues.